ACER THERAPEUTICS INC. Inactive Instrument
Acer Therapeutics Inc.
Equities
ACER
US00444P1084
Biotechnology & Medical Research
Presenter SpeechChristopher Schelling (Executives)Hi, everyone. This is Chris Schelling, the C...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Acer Therapeutics Inc. is a pharmaceutical company, which is focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. The Companyâs product pipeline includes OLPRUVA (sodium phenylbutyrate), ACER-801 (osanetant) and EDSIVO (celiprolol). OLPRUVA (sodium phenylbutyrate) for oral suspension is a formulation of sodium phenylbutyrate powder, for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD). Its ACER-801 (osanetant) is an investigational non-hormonal, neurokinin 3 receptor (NK3R) antagonist for the treatment of asomotor symptoms (VMS), post-traumatic stress disorder (PTSD), and prostate cancer. Its EDSIVO (celiprolol) is a selective adrenergic modulator for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation.
| 1st Jan change | Capi. | |
|---|---|---|
| +9.41% | 114B | |
| +13.34% | 107B | |
| -9.50% | 22.22B | |
| -1.60% | 21.28B | |
| -4.69% | 18.8B | |
| -5.62% | 17.51B | |
| -39.93% | 17.17B | |
| +7.00% | 14.14B | |
| +34.62% | 12.2B |
